

# Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

*Serpin Pharma and HekaBio have signed a term sheet to develop and commercialize SP163M for preventing chemotherapy-induced peripheral neuropathy (CIPN).*

MANASSAS, VIRGINIA, UNITED STATES, July 8, 2024 /EINPresswire.com/ -- [Serpin Pharma](#), a Virginia-based biopharmaceutical company, and [HekaBio](#), headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN).



SP163M, a groundbreaking discovery by Serpin Pharma, is set to revolutionize pain management. This novel therapy protects nerves from the damaging effects of neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. For cancer patients suffering from neuropathy as a side effect of chemotherapy, SP163M offers a critically needed solution. The development of neuropathy often necessitates reducing planned chemotherapy regimens, which may affect cancer outcomes. Preventative therapy could be lifesaving for these patients.

As part of this strategic alliance, HekaBio will spearhead the commercialization of SP163M in critical markets, including Japan, Korea, Taiwan, Australia, ASEAN, the Middle East (excluding Israel), and North Africa. This collaboration integrates Serpin Pharma's prowess in peptide therapeutics with HekaBio's strong presence in the Asian and Australian markets. HekaBio's strategic investment in Serpin Pharma, along with milestone and royalty payments, underscores the mutual commitment to the success of this innovative therapy.

Dr. Cohava Gelber, Founder, Executive Chairperson, and CEO of Serpin Pharma, expressed enthusiasm about the collaboration: "We are thrilled to partner with HekaBio to bring this revolutionary therapy to cancer patients. SP163M can potentially significantly improve the quality of life for those undergoing chemotherapy."

Rob Claar, the CEO of HekaBio, stated: "Our collaboration with Serpin Pharma is inspiring. By combining our complementary capabilities, we aim to deliver a game-changing treatment option for cancer patients suffering from CIPN."

This partnership marks a significant step towards addressing the unmet medical needs for effective CIPN treatments. As the companies advance their development and commercialization plans, cancer patients in the specified regions may soon have access to this innovative therapy.

#### About Serpin Pharma

Serpin Pharma is a private, clinical-stage biopharmaceutical company focused on developing targeted therapeutics based on natural SERPINS (Serine Protease Inhibitors) pivotal for human health. Serpin's drugs aim to revolutionize the treatment of inflammatory diseases by targeting their root cause, restoring immune balance, and inducing cell repair and regeneration.

#### About HekaBio:

HekaBio is a leading Japan-based MedTech and therapeutics in-licensing and commercialization platform. Its mission is to empower patients through accelerated access to global healthcare innovations, which it achieves through its core values of Collaboration, Creativity, and Commitment.

For more information, please contact:

#### Serpin Pharma Contact:

Cohava Gelber, CEO

[cgelber@serpinpharma.com](mailto:cgelber@serpinpharma.com)

[www.SerpinPharma.com](http://www.SerpinPharma.com)

#### HekaBio Contact:

Mari Tanaka, Corporate Communications

[info@Heka.Bio](mailto:info@Heka.Bio)

<https://www.heka.bio/>

Cohava Gelber

Serpin Pharma

+1 7033433258

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/726001297>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.